Share on LinkedInShare on LinkedIn

ARTICLE · 21 SEPTEMBER 2020

China's National Medical Products Administration Proposes Implementing Rules On Patent Linkage For Public Comments

Ropes & Gray LLP
Ropes & Gray LLP
Contributor
Ropes & Gray LLP

Ropes & Gray LLP

Ropes & Gray is one of the world’s most respected law firms, with offices in key business and...

View firm profile
Explore more from Ropes & Gray LLP

The most recent amendment to the Chinese Patent Law describes the general principles of patent linkage, but lacks operational details.

ChinaIntellectual Property

The National Medical Products Administration (NMPA) recently published the draft Measures for Implementing an Early-Stage Resolution Mechanism for Pharmaceutical Patent Disputes (Tentative) (the "Draft Measures"). The agency is soliciting public comments through October 25, 2020. The Draft Measures provide an operating mechanism for the NMPA and the China National IP Administration (CNIPA) to link generic drug applications to pharmaceutical patent protection ("Patent Linkage").

The most recent amendment to the Chinese Patent Law describes the general principles of patent linkage, but lacks operational details. The Draft Measures are intended to answer these operational questions. Contrary to the U.S. Hatch-Waxman Act which provides a mechanism for generic companies to challenge patent exclusivity, the Draft Measures describe a framework for originators to defend their patent exclusivity. If the originators fail to defend their patent exclusivity in time, the NMPA

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from